Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on February 12, 2026, declared Interim Dividend of 1.50 per equity share.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts less than Nifty Smallcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natco Pharma's Board approved Q3FY26 results with consolidated revenue from operations rising ~36% YoY to ₹6,473 million (from ₹4,748 million), driven by a sharp jump in formulations export (₹421.4 Cr vs ₹285.8 Cr in Q3FY25). Consolidated net profit for the quarter grew ~14% to ₹151.3 Crore, with EBITDA (incl. other income) at ₹216.8 Crore and 30.7% margin. However, 9MFY26 PAT fell ~22% YoY to ₹1,149.5 Crore from ₹1,477.4 Crore, weighed down by a weak Q2. The Board declared a third interim dividend of ₹1.50/share (75% on face value of ₹2), with record date Feb 18, 2026 and payment from Feb 26, 2026. Other key items include completion of the 35.75% Adcock Ingram (South Africa) acquisition for US$225 million in Nov 2025, superannuation of CFO S.V.V.N. Appa Rao and appointment of Amit Parekh as new CFO, re-appointment of four directors, and incorporation of a new Chile subsidiary with up to US$300,000 investment.
Strong Q3 revenue growth and a consistent third interim dividend are shareholder-friendly, but the sharp 9M profit decline and large South Africa acquisition introduce execution risk. Near-term, the stock may react to the mixed earnings — robust top-line offset by softer cumulative bottom-line and CFO transition.